Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
复制标题

DOI:
10.1182/blood-2004-06-2181
复制
发表时间:
2005-02-15
期刊:
影响因子:
20.3
通讯作者:
Edelson, RL
Edelson, RL
中科院分区:
医学1区
文献类型:
--
作者:
Berger, CL;Tigelaar, R;Edelson, RL

文献摘要

被引文献

相似文献

皮肤 T 细胞淋巴瘤 (CTCL) 体外模型研究表明,直接接触自体未成熟树突状细胞 (DC) 可刺激 CTCL 细胞增殖,表明 CD4(+) CTCL 细胞分裂是由 DC 主要组织相容性复合体 (MHC) 2 类呈递的抗原驱动。我们现在报道 CD4+ 的 T 细胞受体 (TCR) CTCL 细胞在与负载有凋亡 CTCL 细胞的 DC 相互作用后被触发,如 CD3 和 TCR 膜表达减少、细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 上调以及钙动员所示。 CTCL 细胞采用表达 CD25/CTLA-4 和 FoxP3 并分泌白细胞介素 10 (IL-10) 和转化生长因子 β (TGF-β) 的 T 调节 (Treg) 表型。 Treg CTCL 细胞抑制正常 T 细胞抗原驱动的 IL-2 和干扰素-γ (IFN-gamma) 分泌。阻断 DC MHC 2 类表达或转运可抑制 CTCL 细胞采用 Treg 表型。同种异体 CTCL 细胞或正常 CD4 T 细胞作为 CTCL 细胞转化为 Treg 表型的凋亡材料的来源。 CTCL 细胞向 Treg 细胞的转化可以解释恶性肿瘤的无反应性、免疫抑制性质。 (C) 2005 年,美国血液学会。
Studies in an in vitro model of cutaneous T-cell lymphoma (CTCL) demonstrated that CTCL cell proliferation is stimulated by direct contact with autologous, immature dendritic cells (DCs), suggesting that CD4(+) CTCL cell division is driven by antigens presented by DC major histocompatibility complex (MHC) class 2. We now report that the T-cell receptor (TCR) of the CD4+ CTCL cells is triggered after interaction with DCs loaded with apoptotic CTCL cells, as shown by reduced membrane expression of CD3 and the TCR, up-regulation of cytotoxic T lymphocyte antigen-4 (CTLA-4), and calcium mobilization. CTCL cells adopt a T-regulatory (Treg) phenotype expressing CD25/CTLA-4 and FoxP3 and secreting interieukin-10 (IL-10) and transforming growth factor-beta (TGF-beta). Treg CTCL cells suppress normal T-cell antigen-driven secretion of IL-2 and interferon-gamma (IFN-gamma). Blocking DC MHC class 2 expression or transport inhibited CTCL cell adoption of a Treg phenotype. Allogeneic CTCL cells or normal CD4 T cells served as sources of apoptotic material for CTCL cell conversion to a Treg phenotype. Conversion of CTCL cells to Treg cells may explain the anergic, immunosuppressive nature of the malignancy. (C) 2005 by The American Society of Hematology.